SeaStar Medical Holding (ICU) Research & Development (2022 - 2026)
SeaStar Medical Holding's (ICU) quarterly Research & Development came in at $2.3 million in Q1 2026, down 3.58% YoY from $2.4 million in Q1 2025, and up 6.55% on a QoQ basis from $2.2 million in Q4 2025.
SeaStar Medical Holding (ICU) Research & Development (2022 - 2026) Analysis & Trends
SeaStar Medical Holding (ICU) has 5 years of Research & Development data on file, last reported at $2.3 million in Q1 2026.
- Quarterly Research & Development fell 3.58% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 24.47% YoY) and the FY2025 annual result came in at $7.5 million, down 17.43% from the prior year.
- Research & Development advanced to $2.3 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.7 million in Q4 2024 to a low of $355000.0 in Q1 2022.
- A 5-year average of $1.6 million and a median of $1.7 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development soared 387.32% — and 2025, when it tumbled 55.57%.
- Tracing ICU's Research & Development over 5 years: stood at $825000.0 in 2022, then surged by 42.42% to $1.2 million in 2023, then jumped by 133.02% to $2.7 million in 2024, then retreated by 19.65% to $2.2 million in 2025, then advanced by 6.55% to $2.3 million in 2026.
- The last three Research & Development figures came in at $2.3 million (Q1 2026), $2.2 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 97.90 Mn |
| 10 | SeaStar Medical Holding | 13.89 Mn | 6.89 Mn | 561,000.00 | 2.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.52 Mn |
| Mar 31, 2026 | 2.34 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 1.85 Mn |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 2.43 Mn |
| Dec 31, 2024 | 2.74 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 2.33 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Dec 31, 2023 | 1.18 Mn |
| Sep 30, 2023 | 1.09 Mn |
| Jun 30, 2023 | 1.98 Mn |
| Mar 31, 2023 | 1.73 Mn |
| Dec 31, 2022 | 825,000.00 |
| Sep 30, 2022 | 727,000.00 |
| Jun 30, 2022 | 596,000.00 |
| Mar 31, 2022 | 355,000.00 |